HUP0300725A2 - Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors - Google Patents

Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors

Info

Publication number
HUP0300725A2
HUP0300725A2 HU0300725A HUP0300725A HUP0300725A2 HU P0300725 A2 HUP0300725 A2 HU P0300725A2 HU 0300725 A HU0300725 A HU 0300725A HU P0300725 A HUP0300725 A HU P0300725A HU P0300725 A2 HUP0300725 A2 HU P0300725A2
Authority
HU
Hungary
Prior art keywords
insulin resistance
resistance syndrome
treatment
cgmp pde5
selective cgmp
Prior art date
Application number
HU0300725A
Other languages
Hungarian (hu)
Inventor
David Albert Fryburg
Earl Michael Gibbs
Nandan Parmanand Koppiker
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0030649A external-priority patent/GB0030649D0/en
Priority claimed from GB0106468A external-priority patent/GB0106468D0/en
Priority claimed from GB0106465A external-priority patent/GB0106465D0/en
Priority claimed from GB0117134A external-priority patent/GB0117134D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HUP0300725A2 publication Critical patent/HUP0300725A2/en
Publication of HUP0300725A3 publication Critical patent/HUP0300725A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Egy szelektív cGMP PDE5 inhibitornak vagy egy gyógyászatikompozíciójának alkalmazása az inzulinrezisztencia-szindróma gyógyító,enyhítő vagy megelőző kezelésében használható gyógyszerelőállításában, ahol az inzulinrezisztencia-szindróma jelentése, hogyegy betegnél egyszerre áll fenn a következő kórképek közül legalábbkettő: diszlipidémia; hipertenzió; 2. típusú diabétesz mellitusz,károsult glükóz tolerancia (IGT), vagy a családban előfordulódiabétesz; hiperurikémia és/vagy köszvény; prokoaguláns állapot,ateroszklerózis; vagy törzsi elhízás, és ahol az inzulinrezisztencia-szindrómának vagy az inzulinrezisztencia-szindróma egyéniaspektusainak kezelésében a vegyület vagy kompozíció alkalmazhatóönmagában vagy más ágensekkel kombinálva. ÓThe use of a selective cGMP PDE5 inhibitor or a pharmaceutical composition thereof in the production of a medicine for the curative, mitigating or preventive treatment of insulin resistance syndrome, where insulin resistance syndrome means that a patient has at least two of the following pathologies at the same time: dyslipidemia; hypertension; Type 2 diabetes mellitus, impaired glucose tolerance (IGT), or family history of diabetes; hyperuricemia and/or gout; procoagulant condition, atherosclerosis; or familial obesity, and wherein the compound or composition may be used alone or in combination with other agents in the treatment of insulin resistance syndrome or individual aspects of insulin resistance syndrome. HE

HU0300725A 2000-08-11 2001-08-06 Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors HUP0300725A3 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US22492800P 2000-08-11 2000-08-11
GB0030649A GB0030649D0 (en) 2000-12-15 2000-12-15 Treatment of the insulin resistance syndrome
US26608301P 2001-02-02 2001-02-02
GB0106468A GB0106468D0 (en) 2001-03-15 2001-03-15 Treatment of diabetes mellitus
GB0106465A GB0106465D0 (en) 2001-03-15 2001-03-15 Treatment of the insulin resistance syndrome
GB0117134A GB0117134D0 (en) 2001-07-13 2001-07-13 Treatment of the insulin resistance syndrome
PCT/IB2001/001428 WO2002013798A2 (en) 2000-08-11 2001-08-06 Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors

Publications (2)

Publication Number Publication Date
HUP0300725A2 true HUP0300725A2 (en) 2003-11-28
HUP0300725A3 HUP0300725A3 (en) 2005-11-28

Family

ID=27546614

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300725A HUP0300725A3 (en) 2000-08-11 2001-08-06 Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors

Country Status (9)

Country Link
EP (1) EP1307183A2 (en)
JP (1) JP2004506009A (en)
KR (1) KR20030023747A (en)
CN (1) CN1446084A (en)
AU (1) AU2001276607A1 (en)
CA (1) CA2419033A1 (en)
HU (1) HUP0300725A3 (en)
IL (1) IL154158A0 (en)
WO (1) WO2002013798A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6683080B2 (en) * 2001-02-02 2004-01-27 Pfizer Inc. Treatment of diabetes mellitus
US6933127B2 (en) 2001-07-05 2005-08-23 Eucro European Contract Research Gmbh & Co. Kg Substrate for PP2C
DE10135815A1 (en) * 2001-07-23 2003-02-06 Bayer Ag Use of imidazo-triazinone derivative phosphodiesterase 5 inhibitors e.g. for treatment of cardiac insufficiency, psoriasis, diabetes, cancer, glaucoma, bladder disease, Parkinson's disease or pain
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
BR0213817A (en) * 2001-11-02 2004-10-19 Pfizer Prod Inc Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
US20030181461A1 (en) * 2002-01-25 2003-09-25 Lautt Wilfred Wayne Use of phosphodiesterase antagonists to treat insulin resistance
JP2005519927A (en) * 2002-02-07 2005-07-07 ファイザー・インク Use of a PDE5 inhibitor such as sildenafil in the treatment of polycystic ovary syndrome
JP2004018524A (en) * 2002-06-13 2004-01-22 Eucro European Contract Research Gmbh & Co Kg Method for treating arteriosclerosis
GB0214784D0 (en) * 2002-06-26 2002-08-07 Pfizer Ltd Novel combination
MXPA05009242A (en) * 2003-03-17 2006-04-18 Pfizer Prod Inc Treatment of type 1 diabetes with pde5 inhibitors.
ES2326119T3 (en) 2003-04-29 2009-10-01 Pfizer Inc. 5,7-DIAMINOPIRAZOLO (4,3-D) USEFUL PYRIMIDINS IN THE TREATMENT OF HYPERTENSION.
UA80871C2 (en) * 2003-04-29 2007-11-12 Pfizer Ltd 5,7-diaminopyrazolo[4,3-d]pyrimidines useful in the treatment of hypertension
AU2004269923B2 (en) 2003-09-05 2010-05-13 Takeda Gmbh Use of PDE4 inhibitors for the treatment of diabetes mellitus
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
US7569572B2 (en) 2004-04-07 2009-08-04 Pfizer Inc Pyrazolo[4,3-D]pyrimidines
EP1874308A1 (en) 2005-03-08 2008-01-09 Nycomed GmbH Roflumilast for the treatment of diabetes mellitus
WO2007010337A2 (en) * 2005-07-15 2007-01-25 Proxomed Medizintechnik Gmbh Use of phosphodiesterase type 5 inhibitors for the prevention and treatment of diseases or health disorders and dispensing system for said inhibitors
UA100497C2 (en) 2006-09-07 2013-01-10 Никомед Гмбх Combination treatment for diabetes mellitus
AU2008259342B2 (en) 2007-06-04 2014-07-10 Ben-Gurion University Of The Negev Research And Development Authority Tri-aryl compounds and compositions comprising the same
AT512084A1 (en) 2011-10-20 2013-05-15 Univ Wien Tech DIAZABICYCLO AND DIAZASPIRO ALKAN DERIVATIVES AS PHOSPHODIESTERASE-5 INHIBITORS
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
HUE032613T2 (en) 2012-06-04 2017-10-30 Diamedica Therapeutics Inc Human tissue kallikrein 1 glycosylation isoforms
WO2014078459A1 (en) * 2012-11-13 2014-05-22 Nusirt Sciences, Inc. Compositions and methods for increasing energy metabolism
CA2851912C (en) * 2013-05-14 2022-08-30 Scimar Ltd. Hepatic insulin sensitizing substance and test meal for insulin sensitization
JP6657101B2 (en) 2013-11-05 2020-03-04 ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ Compounds for the treatment of diabetes and disease complications resulting therefrom
EP3592377A4 (en) 2017-03-09 2021-02-17 Diamedica Inc. Dosage forms of tissue kallikrein 1
MX2017016930A (en) * 2017-12-19 2019-06-20 Malesil Research & Tech Llc Method of treatment of diabetic foot ulcers.
KR102068299B1 (en) 2018-12-21 2020-01-20 한국기초과학지원연구원 A pharmaceutical composition for prevention or treatment of metabolic disease comprising CYP4A inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
CN1211238A (en) * 1995-12-28 1999-03-17 藤泽药品工业株式会社 Benzimidazole derivatives
NZ338075A (en) * 1997-04-25 2000-10-27 Pfizer Ltd Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PED5) for the treatment of sexual dysfunction
WO1999000372A1 (en) * 1997-06-27 1999-01-07 Fujisawa Pharmaceutical Co., Ltd. Sulfonamide compounds and medicinal use thereof
WO1999051574A1 (en) * 1998-04-06 1999-10-14 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives
WO2000034277A1 (en) * 1998-12-04 2000-06-15 Fujisawa Pharmaceutical Co., Ltd. Sulfonamide compounds and uses thereof as medicines
CN1161341C (en) * 1999-03-22 2004-08-11 布里斯托尔-迈尔斯斯奎布公司 Fused pydiopyridazine inhibitors of cGMP phosphodiesterase
DE19944161A1 (en) * 1999-09-15 2001-03-22 Bayer Ag New combination for the treatment of sexual dysfunction
ES2211454T3 (en) * 1999-09-30 2004-07-16 Pfizer Products Inc. PIRROLILAMIDS AS INHIBITORS OF THE FOSFORILASA COLLAGEN.
US6503908B1 (en) * 1999-10-11 2003-01-07 Pfizer Inc Pharmaceutically active compounds
WO2001078781A2 (en) * 2000-04-19 2001-10-25 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders

Also Published As

Publication number Publication date
CN1446084A (en) 2003-10-01
CA2419033A1 (en) 2002-02-21
KR20030023747A (en) 2003-03-19
EP1307183A2 (en) 2003-05-07
AU2001276607A1 (en) 2002-02-25
JP2004506009A (en) 2004-02-26
WO2002013798A2 (en) 2002-02-21
IL154158A0 (en) 2003-07-31
HUP0300725A3 (en) 2005-11-28
WO2002013798A3 (en) 2003-01-23

Similar Documents

Publication Publication Date Title
HUP0300725A2 (en) Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors
HUP0401998A2 (en) The use of pde 9 inhibitors for production of those medicine being useful in the treatment of insulin resistance syndrome and type 2 diabetes
MXPA04004837A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1.
HK1121074A1 (en) Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione
EP1545483A4 (en) Non-nucleoside reverse transcriptase inhibitors
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
TNSN05065A1 (en) Use of prebiotics for the treatment and prevention of hyperglycaemic syndromes
MY138708A (en) Biaryloxymethylarenecarboxylic acids
WO2002004421A3 (en) Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
ME00578A (en) Use of gastrointestinal lipase inhibitors
WO2005107467A3 (en) Compositions including opioids and methods of their use in treating pain
NO20035602D0 (en) A composition comprising a PDE-4 inhibitor and H1 receptor antagonist, as well as its use in the preparation of a medicament for the treatment of respiratory diseases.
EP1452176A4 (en) Insulin resistance improving agents
EP1422240A3 (en) Analogs of nociceptin
BRPI0410761A (en) leucine, and composition for enteral administration to patients
TW200503676A (en) Use of kynurenine 3-hydroxylase inhibitors for the treatment of diabetes
MXPA05006408A (en) Deuterated catecholamine derivatives and medicaments comprising said compounds.
GB0606001D0 (en) Combination Of Cicletanine And An Oral Antidiabetic And/Or Blood Lipid-Lowering Agent For Treating Diabetes And Metabolic Syndrome
WO2008068778A3 (en) Extended release pharmaceutical composition of pramipexole
WO2007077454A3 (en) A therapeutic composition comprising an inhibitor of an hsp 90 protein
MXPA04005033A (en) Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes.
NO20074767L (en) Use of rimonabant for the preparation of drugs that can be used in the prevention and treatment of type 2 diabetes
MX2007012991A (en) Crystalline solid and amorphous forms of (-)- halofenate.
DK2014290T3 (en) Use of tenatoprazole in the treatment of gastroesophageal reflux
HUP0402645A2 (en) Pharmaceutical composition comprising a glitazone and 4-oxobutanoic acid, and the use thereof for treating diabetes

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees